Question to the HM Treasury:

To ask the Chancellor of the Exchequer, whether she has had recent discussions with the Secretary of State for Health and Social Care on the (a) cost to the NHS of prescribing weight loss medications and (b) the projected cost savings from reduced obesity-related illness.

The Chancellor regularly discusses a wide range of policy issues with the Secretary of State for Health and Social Care.

For medicines to be provided by the NHS they must meet strict cost-effectiveness thresholds set by NICE. For tirzepatide, a weightloss jab, evidence submitted by NHS England to NICE last year suggested a potential cost of £19.4bn for the drug, the patient management and the associated care over the first five years from launch if made available to all eligible patients. The NHS is working with partners, including supplies of medicines for weight management, to develop and evaluate innovative delivery models which may support more efficient implementation

NICE recommended the NHS begin rolling out trizepatide, for people with a BMI of more than 35 and at least one weight-related illness. In total around 220,000 people are expected to benefit in the initial three year roll out period.

The obesity crisis currently costs the NHS an estimated £11.4 billion per year and has significant wider economic and social costs, so tackling this will help to drive long term economic growth.

That is why the 10 year health plan, published on 3rd July 2025, set out Government’s plans for decisive action on the obesity crisis, easing the strain on our NHS and creating the healthiest generation of children ever.

The Plan sets out a commitment to support people living with obesity, doubling the number of patients able to access the NHS Digital Weight Management Programme and brokering pioneering relationships with the biggest pharmaceutical companies to expand access to weight loss services and treatments across the NHS.

The Plan also committed to fulfilling manifesto commitments to restrict junk food advertising and ban sale of high-caffeine drinks. Additionally it announced new proposals to reduce obesity including for large food businesses to report against standardised metrics on healthier food sales along with new targets to increase the healthiness of sales, and updating the Nutrient Profile Model to bring the current advertising and promotion restrictions up to date and make them more impactful.